pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
476
stories
29d
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
stat
29d
STAT+: Pharmalittle: We’re reading about Beam suing over IP theft, a Trump rule on importing meds, and more
stat
29d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
29d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
Sep 29, 26
STAT+: Lawmakers urge Trump to rethink new rule that could restrict imported meds from Canada and overseas
stat
Sep 29, 26
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
Sep 29, 26
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
Sep 29, 26
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
Sep 29, 26
STAT+: Pharmalittle: We’re reading about Novo licensing a Chinese obesity pill, Merck pulling an antibiotic, and more
stat
Sep 29, 26
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
Sep 29, 26
Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug
endpoints
Sep 29, 26
Biopharma recruiters see ‘signs of recovery’ as layoffs remain cool in Q3’26
fiercebiotech
Sep 29, 26
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
fiercebiotech
Sep 29, 26
Recon: FDA approves Egetis’ Emcitate for rare genetic disease; Novo buys rights to Chinese weight-loss pill in $2.6B deal
raps
Sep 28, 26
STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistance
stat
Sep 28, 26
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
Sep 28, 26
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
Sep 28, 26
Trump uses ‘contested’ power to cut more funding to HHS
stat
Sep 28, 26
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
Sep 28, 26
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
Sep 28, 26
6 immunology targets to sustain a mammoth I&I market
biospace
Sep 26, 26
The drug industry’s care gap; Novo aims to diversify; and more
endpoints
Sep 25, 26
STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
stat
Sep 25, 26
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
biopharma dive
Sep 25, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Sep 25, 26
STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
stat
Sep 25, 26
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
biopharma dive
Sep 25, 26
Novo does another small deal, this time with drug delivery biotech Nanexa
endpoints
Sep 25, 26
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
fiercebiotech
Sep 24, 26
Pioneer of China NewCo model sued in US over trade secret misuse, double-dealing
fiercebiotech
← prev
page 4 of 16
next →
